{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:11:06Z","timestamp":1679231466742},"reference-count":28,"publisher":"Becaris Publishing Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            To examine the factors related to the comparative effectiveness of clozapine.\n            <jats:bold>Patients &amp; methods:<\/jats:bold>\n            US insurance claims databases were used to identify schizophrenia patients. To examine the factors modifying the comparative effectiveness of clozapine in relation to other second-generation antipsychotics, a series of variables were interacted with a clozapine indicator in regressions.\n            <jats:bold>Results:<\/jats:bold>\n            The impacts of clozapine on both persistence and adherence were significantly modified by prior hospitalization, prior epilepsy diagnosis and prior use of antianginal agents. The relative risks of heavy inpatient services use and heavy emergency department services use were also modified by several factors.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Several factors can be used to identify patients who are more likely to benefit from clozapine than other second-generation antipsychotics.\n          <\/jats:p>","DOI":"10.2217\/cer-2018-0096","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T12:01:20Z","timestamp":1546948880000},"page":"179-185","source":"Crossref","is-referenced-by-count":0,"title":["Factors related to the comparative effectiveness of clozapine in patients with schizophrenia"],"prefix":"10.57264","volume":"8","author":[{"given":"Yawen","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical &amp; Health Economics, School of Pharmacy, University of Southern California, USC Schaeffer Center, Verna &amp; Peter Dauterive Hall (VPD), 635 Downey Way, Los Angeles, CA 90089-3333, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyi","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical &amp; Health Economics, School of Pharmacy, University of Southern California, USC Schaeffer Center, Verna &amp; Peter Dauterive Hall (VPD), 635 Downey Way, Los Angeles, CA 90089-3333, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"2","key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1176\/appi.ps.201300180","article-title":"Geographic and clinical variation in clozapine use in the United States","volume":"65","author":"Stroup TS","year":"2014","unstructured":"Stroup TS , Gerhard T , Crystal S , Huang C , Olfson M . Geographic and clinical variation in clozapine use in the United States . Psychiatr. Serv. 65 ( 2 ), 186 \u2013 192 ( 2014 ).","journal-title":"Psychiatr. Serv."},{"issue":"4","key":"e_1_3_3_4_2","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy J","year":"2006","unstructured":"McEvoy J , Lieberman J , Stroup T Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment . Am. J. Psych. 163 ( 4 ), 600 \u2013 610 ( 2006 ).","journal-title":"Am. J. Psych."},{"issue":"10","key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","article-title":"Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study","volume":"5","author":"Kahn RS","year":"2018","unstructured":"Kahn RS , Van Rossum IW , Leucht S Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study . Lancet Psych. 5 ( 10 ), 797 \u2013 807 ( 2018 ).","journal-title":"Lancet Psych."},{"issue":"4","key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/npp.2016.258","article-title":"Presynaptic dopamine capacity in patients with treatment-resistant schizophrenia taking clozapine: an [18 F] DOPA PET Study","volume":"42","author":"Kim E","year":"2017","unstructured":"Kim E , Howes OD , Veronese M Presynaptic dopamine capacity in patients with treatment-resistant schizophrenia taking clozapine: an [18 F] DOPA PET Study . Neuropsychopharmacology 42 ( 4 ), 941 ( 2017 ).","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"e_1_3_3_7_2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1176\/appi.ps.201200041","article-title":"The effect of race-ethnicity on the comparative effectiveness of clozapine among Medicaid beneficiaries","volume":"64","author":"Horvitz-Lennon M","year":"2013","unstructured":"Horvitz-Lennon M , Donohue JM , Lave JR , Alegria M , Normand SL . The effect of race-ethnicity on the comparative effectiveness of clozapine among Medicaid beneficiaries . Psychiatr. Serv. 64 ( 3 ), 230 \u2013 237 ( 2013 ).","journal-title":"Psychiatr. Serv."},{"issue":"4","key":"e_1_3_3_8_2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1192\/apt.bp.110.008128","article-title":"Underuse of clozapine in treatment-resistant schizophrenia","volume":"17","author":"Mistry H","year":"2011","unstructured":"Mistry H , Osborn D . Underuse of clozapine in treatment-resistant schizophrenia . Adv. Psychiatr. Treat. 17 ( 4 ), 250 \u2013 255 ( 2011 ).","journal-title":"Adv. Psychiatr. Treat."},{"issue":"1","key":"e_1_3_3_9_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","article-title":"Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT)","volume":"60","author":"Meltzer HY","year":"2003","unstructured":"Meltzer HY , Alphs L , Green AI Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT) . Arch. Gen. Psych. 60 ( 1 ), 82 \u2013 91 ( 2003 ).","journal-title":"Arch. Gen. Psych."},{"issue":"9","key":"e_1_3_3_10_2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/phar.1634","article-title":"Estimating the impact of adherence to and persistence with atypical antipsychotic therapy on health care costs and risk of hospitalization","volume":"35","author":"Jiang Y","year":"2015","unstructured":"Jiang Y , Ni W . Estimating the impact of adherence to and persistence with atypical antipsychotic therapy on health care costs and risk of hospitalization . Pharmacotherapy 35 ( 9 ), 813 \u2013 822 ( 2015 ).","journal-title":"Pharmacotherapy"},{"issue":"1","key":"e_1_3_3_11_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/10401230309085668","article-title":"Clozapine: a clinical review of adverse effects and management","volume":"15","author":"Iqbal MM","year":"2003","unstructured":"Iqbal MM , Rahman A , Husain Z , Mahmud SZ , Ryan WG , Feldman JM . Clozapine: a clinical review of adverse effects and management . Ann. Clin. Psych. 15 ( 1 ), 33 \u2013 48 ( 2003 ).","journal-title":"Ann. Clin. Psych."},{"issue":"1","key":"e_1_3_3_12_2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2174\/157015912799362724","article-title":"Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review","volume":"10","author":"Schirmbeck F","year":"2012","unstructured":"Schirmbeck F , Zink M . Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review . Curr. Neuropharmacol. 10 ( 1 ), 88 \u2013 95 ( 2012 ).","journal-title":"Curr. Neuropharmacol."},{"issue":"11","key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1176\/appi.ps.201100435","article-title":"Factors associated with initiation on clozapine and on other antipsychotics among Medicaid enrollees","volume":"63","author":"Manuel JI","year":"2012","unstructured":"Manuel JI , Essock SM , Wu Y , Pangilinan M , Stroup S . Factors associated with initiation on clozapine and on other antipsychotics among Medicaid enrollees . Psychiatr. Serv. 63 ( 11 ), 1146 \u2013 1149 ( 2012 ).","journal-title":"Psychiatr. Serv."},{"issue":"10","key":"e_1_3_3_14_2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1192\/pb.29.10.377","article-title":"Clozapine prescribing in adolescent psychiatry: survey of prescribing practice in in-patient units","volume":"29","author":"Cirulli G","year":"2005","unstructured":"Cirulli G . Clozapine prescribing in adolescent psychiatry: survey of prescribing practice in in-patient units . Psych. Bull. 29 ( 10 ), 377 \u2013 380 ( 2005 ).","journal-title":"Psych. Bull."},{"issue":"7","key":"e_1_3_3_15_2","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/0269881108100320","article-title":"Psychiatrists\u2019 attitude towards and knowledge of clozapine treatment","volume":"24","author":"Nielsen J","year":"2010","unstructured":"Nielsen J , Dahm M , Lublin H , Taylor D . Psychiatrists\u2019 attitude towards and knowledge of clozapine treatment . J. Psychopharmacol. 24 ( 7 ), 965 \u2013 971 ( 2010 ).","journal-title":"J. Psychopharmacol."},{"issue":"12","key":"e_1_3_3_16_2","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1176\/ajp.151.12.1744","article-title":"Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome","volume":"151","author":"Lieberman JA","year":"1994","unstructured":"Lieberman JA , Safferman AZ , Pollack S Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome . Am. J. Psych. 151 ( 12 ), 1744 \u2013 1752 ( 1994 ).","journal-title":"Am. J. Psych."},{"issue":"9","key":"e_1_3_3_17_2","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1176\/ps.62.9.pss6209_1032","article-title":"Adherence, persistence of use, and costs associated with second-generation antipsychotics for bipolar disorder","volume":"62","author":"Rascati KL","year":"2011","unstructured":"Rascati KL , Richards KM , Ott CA Adherence, persistence of use, and costs associated with second-generation antipsychotics for bipolar disorder . Psychiatr. Serv. 62 ( 9 ), 1032 \u2013 1040 ( 2011 ).","journal-title":"Psychiatr. Serv."},{"key":"e_1_3_3_18_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/CEOR.S36526","article-title":"Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy","volume":"5","author":"Nadkarni A","year":"2013","unstructured":"Nadkarni A , Kalsekar I , You M , Forbes R , Hebden T . Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy . Clinicoecon. Outcomes Res. 5 , 49 \u2013 57 ( 2013 ).","journal-title":"Clinicoecon. Outcomes Res."},{"issue":"1","key":"e_1_3_3_19_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-3-21","article-title":"Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs","volume":"3","author":"Liu-Seifert H","year":"2005","unstructured":"Liu-Seifert H , Adams D , Kinon B . Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs . BMC Med. 3 ( 1 ), 1 \u2013 10 ( 2005 ).","journal-title":"BMC Med."},{"issue":"8","key":"e_1_3_3_20_2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.4088\/JCP.v68n0801","article-title":"Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder","volume":"68","author":"Dunayevich E","year":"2007","unstructured":"Dunayevich E , Ascher-Svanum H , Zhao F Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder . J. Clin. Psych. 68 ( 8 ), 1163 \u2013 1171 ( 2007 ).","journal-title":"J. Clin. Psych."},{"issue":"1","key":"e_1_3_3_21_2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1524-4733.2007.00212.x","article-title":"The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia","volume":"11","author":"Chen L","year":"2008","unstructured":"Chen L , Mccombs JS , Park J . The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia . Value Health 11 ( 1 ), 34 \u2013 43 ( 2008 ).","journal-title":"Value Health"},{"issue":"8","key":"e_1_3_3_22_2","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1176\/appi.ps.55.8.886","article-title":"Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia","volume":"55","author":"Weiden PJ","year":"2004","unstructured":"Weiden PJ . Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia . Psychiatr. Serv. 55 ( 8 ), 886 \u2013 891 ( 2004 ).","journal-title":"Psychiatr. Serv."},{"issue":"7","key":"e_1_3_3_23_2","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1345\/aph.1H018","article-title":"Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures","volume":"40","author":"Hess LM","year":"2006","unstructured":"Hess LM , Raebel MA , Conner DA , Malone DC . Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures . Ann. Pharmacother. 40 ( 7-8 ), 1280 \u2013 1288 ( 2006 ).","journal-title":"Ann. Pharmacother."},{"key":"e_1_3_3_24_2","unstructured":"Nau\n                                                DP\n                                        . \n                                        Proportion of days covered (PDC) as a preferred method of measuring medication adherence\n                                        . \n                                        www.pqaalliance.org\/files\/PDCvsMPRfinal.pdf\n                                         (\n                                        2012\n                                        )."},{"issue":"4","key":"e_1_3_3_25_2","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/1475-6773.12162","article-title":"Disparities in quality of care among publicly insured adults with schizophrenia in four large U.S. states, 2002\u20132008","volume":"49","author":"Horvitz-Lennon M","year":"2014","unstructured":"Horvitz-Lennon M , Volya R , Donohue JM , Lave JR , Stein BD , Normand S-LT . Disparities in quality of care among publicly insured adults with schizophrenia in four large U.S. states, 2002\u20132008 . Health Serv. Res. 49 ( 4 ), 1121 \u2013 1144 ( 2014 ).","journal-title":"Health Serv. Res."},{"issue":"11","key":"e_1_3_3_26_2","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan H","year":"2005","unstructured":"Quan H , Sundararajan V , Halfon P Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data . Medical Care 43 ( 11 ), 1130 \u2013 1139 ( 2005 ).","journal-title":"Medical Care"},{"key":"e_1_3_3_27_2","unstructured":"Place of service codes for professional claims\n                                        MD USA\n                                        : \n                                        Centers for medicare & medicaid services\n                                        ; \n                                        www.cms.gov\/Medicare\/Coding\/place-of-service-codes\/Place_of_Service_Code_Set.html\n                                         (\n                                        2014\n                                        )."},{"key":"e_1_3_3_28_2","volume-title":"Propensity Score Analysis: Statistical Methods and Applications","author":"Guo S","year":"2009","unstructured":"Guo S , Fraser MW . Propensity Score Analysis: Statistical Methods and Applications . SAGE Publications , CA, USA ( 2009 )."},{"issue":"4","key":"e_1_3_3_29_2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1536867X0200200403","article-title":"Estimation of average treatment effects based on propensity scores","volume":"2","author":"Becker SO","year":"2002","unstructured":"Becker SO , Ichino A . Estimation of average treatment effects based on propensity scores . Stata J. 2 ( 4 ), 358 \u2013 377 ( 2002 ).","journal-title":"Stata J."},{"issue":"11","key":"e_1_3_3_30_2","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1185\/030079907X233322","article-title":"Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder","volume":"23","author":"Zhu B","year":"2007","unstructured":"Zhu B , Kulkarni PM , Stensland MD , Ascher-Svanum H . Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder . Curr. Med. Res. Opin. 23 ( 11 ), 2805 \u2013 2814 ( 2007 ).","journal-title":"Curr. Med. Res. Opin."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2018-0096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T12:36:44Z","timestamp":1679229404000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2018-0096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.2217\/cer-2018-0096"],"URL":"https:\/\/doi.org\/10.2217\/cer-2018-0096","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}